Table 3.
Impact of patient, tumors, and treatment parameters on 5 years biochemical disease-free survival (univariate analysis)
| No. | % | 5-year bDFS (%) | p | |
|---|---|---|---|---|
| Age, years | ||||
| ≤65 | 72 | 58.5 | 92.0 | 0.166 |
| >65 | 51 | 41.5 | 93.9 | |
| pT | ||||
| 2 | 17 | 13.8 | 92.3 | 0.515 |
| 3–4 | 106 | 86.2 | 93.2 | |
| pN | ||||
| 0 | 79 | 64.2 | 93.6 | 0.674 |
| 1 | 18 | 14.6 | 90.0 | |
| X | 26 | 21.1 | 91.3 | |
| Margins status | ||||
| R0 | 51 | 41.5 | 93.1 | 0.441 |
| R1 | 72 | 58.5 | 92.9 | |
| Perineural infiltration | ||||
| No | 47 | 38.2 | 93.9 | 0.115 |
| Yes | 76 | 61.8 | 92.6 | |
| PSA pre-surgery, µg/L | ||||
| ≤ 10 | 69 | 56.1 | 92.0 | 0.391 |
| > 10 | 54 | 43.9 | 93.9 | |
| PSA (post surgery), µg/L | ||||
| ≤ 0.2 | 114 | 92.7 | 93.2 | 0.602 |
| > 0.2 | 9 | 7.3 | 88.9 | |
| Histopathologic grade, Gleason score | ||||
| ≤ 7 | 92 | 74.8 | 95.5 | 0.001 |
| 8–10 | 31 | 25.2 | 85.5 | |
| Lymphadenectomy | ||||
| No | 26 | 21.1 | 91.3 | 0.499 |
| Yes | 97 | 78.9 | 93.3 | |
| Radiotherapy dose to prostatic bed, Gy | ||||
| 64.8 | 18 | 14.6 | 91.7 | 0.543 |
| 70.2 | 105 | 85.4 | 93.1 | |
| Prophylactic nodal irradiation | ||||
| No | 52 | 42.3 | 96.2 | 0.273 |
| Yes | 71 | 57.7 | 90.3 | |
| Adjuvant hormone therapy | ||||
| No | 38 | 30.9 | 91.3 | 0.486 |
| Yes | 85 | 69.1 | 93.7 | |
| Adjuvant hormone therapy | ||||
| Bicalutamide | 48 | 39.0 | 92.7 | 0.611 |
| LH-RH analog | 37 | 30.1 | 94.1 | |
| Adjuvant hormone therapy | ||||
| Short-term (6 months) | 23 | 27.1 | 100.0 | 0.183 |
| Long-term (24 months) | 62 | 72.9 | 91.8 | |
bDFS biochemical disease-free survival, N number of patients, PSA prostate-specific antigen
The bold entry was to emphasis the significant p valve